EP2114160A4 - ANTAGONISTS OF A NON-SELECTIVE CATIONIC CHANNEL IN NEURAL CELLS - Google Patents
ANTAGONISTS OF A NON-SELECTIVE CATIONIC CHANNEL IN NEURAL CELLSInfo
- Publication number
- EP2114160A4 EP2114160A4 EP08729376.7A EP08729376A EP2114160A4 EP 2114160 A4 EP2114160 A4 EP 2114160A4 EP 08729376 A EP08729376 A EP 08729376A EP 2114160 A4 EP2114160 A4 EP 2114160A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- antagonists
- neural cells
- cationic channel
- selective cationic
- selective
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US88906507P | 2007-02-09 | 2007-02-09 | |
| US95017007P | 2007-07-17 | 2007-07-17 | |
| PCT/US2008/053405 WO2008098160A1 (en) | 2007-02-09 | 2008-02-08 | Antagonists of a non-selective cation channel in neural cells |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| EP2114160A1 EP2114160A1 (en) | 2009-11-11 |
| EP2114160A4 true EP2114160A4 (en) | 2013-12-11 |
| EP2114160B1 EP2114160B1 (en) | 2016-11-16 |
Family
ID=39678567
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP08729376.7A Active EP2114160B1 (en) | 2007-02-09 | 2008-02-08 | Antagonists of a non-selective cation channel in neural cells |
Country Status (4)
| Country | Link |
|---|---|
| US (2) | US20100092469A1 (en) |
| EP (1) | EP2114160B1 (en) |
| CA (1) | CA2618099C (en) |
| WO (1) | WO2008098160A1 (en) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1529058B1 (en) | 2002-03-20 | 2013-11-06 | University of Maryland Baltimore | A non-selective cation channel in neural cells and sur1 antagonists for treating brain swelling |
| US8980952B2 (en) * | 2002-03-20 | 2015-03-17 | University Of Maryland, Baltimore | Methods for treating brain swelling with a compound that blocks a non-selective cation channel |
| US10583094B2 (en) * | 2004-09-18 | 2020-03-10 | University Of Maryland | Therapeutic methods that target the NCCA-ATP channel |
| CA2674949A1 (en) | 2007-01-12 | 2008-07-24 | J. Marc Simard | Targeting ncca-atp channel for organ protection following ischemic episode |
| EP2167107B1 (en) * | 2007-06-22 | 2016-12-14 | University of Maryland, Baltimore | Inhibitors of ncca-atp channels for therapy |
| EP2326318A4 (en) * | 2008-09-16 | 2012-05-23 | Univ Maryland | SUR1 INHIBITORS FOR THERAPY |
| CA2804154C (en) * | 2010-07-01 | 2021-06-01 | The Texas A&M University System | Perlecan domain v protects, repairs and restores ischemic brain stroke injury and motor function |
| EP2609914A1 (en) | 2011-12-29 | 2013-07-03 | Universitätsklinikum Hamburg-Eppendorf | Novel methods for treating or preventing neurodegeneration |
| ES2699646T3 (en) | 2012-05-08 | 2019-02-12 | Aeromics Inc | Compounds for use in the treatment of aquaporin-mediated diseases |
| JP6073125B2 (en) * | 2012-12-20 | 2017-02-01 | 国立大学法人 岡山大学 | Preventive or therapeutic agent for ischemic disease |
| WO2014209239A1 (en) * | 2013-06-28 | 2014-12-31 | Singapore Health Services Pte Ltd | Trpm4 channel inhibitors for stroke treatment |
| HK1224228A1 (en) | 2013-11-06 | 2017-08-18 | Aeromics, Inc. | Novel formulations |
| CA2951721C (en) * | 2014-06-12 | 2023-09-26 | The Research Foundation For The State University Of New York | Methods of using gap junctions as therapeutic targets for the treatment of degenerative disorders of the retina |
| KR102618123B1 (en) * | 2015-05-29 | 2023-12-27 | 유니버시티 오브 매릴랜드, 발티모어 | Methods for reducing or preventing intimal damage caused by mechanical stimulation of endothelial cells |
| AU2017301736A1 (en) * | 2016-07-29 | 2019-03-14 | Biogen Chesapeake Llc | Methods of treating or preventing amyloid related imaging abnormalities associated with alzheimer's disease treatment |
| WO2018023035A1 (en) * | 2016-07-29 | 2018-02-01 | Biogen Chesapeake Llc | Methods of medical treatment with sur1-trpm4 channel inhibitors |
| IL312394B2 (en) * | 2017-08-18 | 2025-07-01 | Regeneron Pharma | Image capillary isoelectric focusing to analyze protein variants in a sample matrix |
| EP3758692B1 (en) * | 2018-02-27 | 2024-08-21 | University of Maryland, Baltimore | Compositions and methods for treating pain |
| WO2019177099A1 (en) * | 2018-03-15 | 2019-09-19 | 株式会社マンダム | Method for evaluating test sample |
| US20210261971A1 (en) * | 2018-06-25 | 2021-08-26 | University Of Southern California | Compositions and methods for ameliorating tissue injury, enhancing liver regeneration and stem cell therapies |
| WO2020041905A1 (en) * | 2018-08-31 | 2020-03-05 | The University Of British Columbia | Methods for identifying compounds suitable for treatment of central nervous system trauma and uses of those compounds |
| KR102248420B1 (en) * | 2019-03-15 | 2021-05-06 | 주식회사 제너로스 | Recombinant vector containing target sequence for miR-142-3p |
| EP4114372A1 (en) * | 2020-03-04 | 2023-01-11 | Neucures, Inc. | Use of qx314 to prevent sympathoexcitation associated with administration of trpv1 modulators |
| CN112730849B (en) * | 2021-01-14 | 2023-03-10 | 山西医科大学第二医院 | Application of endogenous orphan enkephalin as serum biomarker for diabetes mellitus combined with asymptomatic myocardial ischemia |
| CN114487403B (en) * | 2021-12-20 | 2025-01-28 | 山东第一医科大学第二附属医院 | A test strip for simultaneously detecting MMP-9 and Occludin in blood and a preparation method thereof |
| US12251389B1 (en) | 2024-04-22 | 2025-03-18 | Remedy Pharmaceuticals, Inc. | Methods of treating ischemic stroke at risk for cerebral or cerebellar edema |
| US12251388B1 (en) | 2024-05-09 | 2025-03-18 | Remedy Pharmaceuticals, Inc. | Methods of treating ischemic stroke at risk for cerebral or cerebellar edema |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003057843A2 (en) * | 2001-12-31 | 2003-07-17 | Algos Therapeutics, Inc. | Methods and materials for modulating trpc4 |
| US20060276411A1 (en) * | 2002-03-20 | 2006-12-07 | University Of Maryland, Baltimore | Novel non-selective cation channel in neuronal cells and methods for treating brain swelling |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8809205D0 (en) * | 1988-04-19 | 1988-05-25 | Nye P C G | Treatment of oedema |
| US5166162A (en) * | 1990-03-02 | 1992-11-24 | Adir Et Compagnie | Pyridylsulfonylurea and pyridylsulfonylthiourea compounds |
| US5466468A (en) | 1990-04-03 | 1995-11-14 | Ciba-Geigy Corporation | Parenterally administrable liposome formulation comprising synthetic lipids |
| CA2044853C (en) * | 1990-07-19 | 2004-11-09 | Susan A. Greenfield | Method for treating parkinson's disease employing an atp-sensitive potassium channel blocker |
| US5236932A (en) * | 1990-07-19 | 1993-08-17 | E. R. Squibb & Sons, Inc. | Method for treating Parkinson's disease employing quinine |
| US5215985A (en) * | 1990-07-20 | 1993-06-01 | E. R. Squibb & Sons, Inc. | Method for treating ischemic insult to neurons employing an ATP-sensitive potassium channel blocker |
| JPH06502538A (en) * | 1990-10-16 | 1994-03-24 | ザ チルドレンズメディカルセンターコーポレーション | Heparin-binding mitogen with homology to epidermal growth factor (EGF) |
| US5399363A (en) | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
| US5916871A (en) * | 1992-04-27 | 1999-06-29 | Kansas State University Research Foundation | Inhibitory factor |
| US5792451A (en) | 1994-03-02 | 1998-08-11 | Emisphere Technologies, Inc. | Oral drug delivery compositions and methods |
| US5543158A (en) | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
| DE4430212A1 (en) * | 1994-08-28 | 1996-02-29 | Merck Patent Gmbh | Ortho-substituted benzoic acid derivatives |
| US5580579A (en) | 1995-02-15 | 1996-12-03 | Nano Systems L.L.C. | Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers |
| US20010003751A1 (en) * | 1995-02-22 | 2001-06-14 | Terashita Zen-Ichi | Pharmaceutical composition for treating transient ischemic attack |
| AUPN193095A0 (en) * | 1995-03-24 | 1995-04-27 | Polychip Pharmaceuticals Pty Ltd | Potassium ion channel blockers |
| IE80468B1 (en) | 1995-04-04 | 1998-07-29 | Elan Corp Plc | Controlled release biodegradable nanoparticles containing insulin |
| US5545656A (en) * | 1995-04-05 | 1996-08-13 | Pfizer Inc. | 2-Oxidole-1-carboxamide pharmaceutical agents for the treatment of alzheimer's disease |
| US7608262B2 (en) * | 1996-02-16 | 2009-10-27 | The Kennedy Institute Of Rheumatology | Methods of preventing or treating thrombosis with tumor necrosis factor antagonists |
| EP1006798A4 (en) * | 1996-09-05 | 2003-03-05 | Massachusetts Inst Technology | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS AND NEURODEGENERATIVE DISEASES |
| US6184248B1 (en) * | 1996-09-05 | 2001-02-06 | Robert K. K. Lee | Compositions and methods for treatment of neurological disorders and neurodegenerative diseases |
| US5962645A (en) * | 1996-10-04 | 1999-10-05 | University Of Maryland | Antiproliferative factor from patients with interstitial cystitis |
| US20020016443A1 (en) * | 1996-10-04 | 2002-02-07 | Keay Susan K. | Antiproliferative factor |
| AU8283898A (en) * | 1997-06-30 | 1999-01-25 | University Of Maryland At Baltimore | Heparin binding-epidermal growth factor in the diagnosis of interstitial cystitis |
| US6056977A (en) * | 1997-10-15 | 2000-05-02 | Edward Mendell Co., Inc. | Once-a-day controlled release sulfonylurea formulation |
| US6679859B1 (en) * | 1997-10-24 | 2004-01-20 | Alliance Pharmaceutical Corp. | Amelioration of ischemic damage using synthetic oxygen carriers |
| US6569845B1 (en) * | 1997-12-26 | 2003-05-27 | Mochida Pharmaceutical Co., Ltd. | Neovascularization inhibitor containing dienogest as the active ingredient |
| US6180671B1 (en) * | 1998-03-10 | 2001-01-30 | Beth Israel Deaconess Medical Center, Inc. | Methods for treating disorders in which docosahexaenoic acid (DHA) levels are affected |
| US6100047A (en) * | 1999-04-07 | 2000-08-08 | Zen Bio, Inc. | Modulation of the sulfonylurea receptor and calcium in adipocytes for treatment of obesity/diabetes |
| JP2002512259A (en) * | 1998-04-17 | 2002-04-23 | ユニバーシティ・オブ・メリーランド， ボルティモア | Method for treating interstitial cystitis with recombinant heparin-binding epidermal growth factor-like growth factor (HB-EGF) |
| US6613785B2 (en) * | 1998-07-21 | 2003-09-02 | Smithkline Beecham Plc | Use of glucose uptake enhancer for reducing post-ischemic injury of the heart |
| ATE332969T1 (en) * | 1998-10-26 | 2006-08-15 | Avi Biopharma Inc | MORPHOLINE-BASED P53 ANTISENSE OLIGONUCLEOTIDE AND USES THEREOF |
| CN1208323C (en) * | 1999-04-06 | 2005-06-29 | 三共株式会社 | Alpha-substituted carboxylic acid derivatives |
| WO2000069823A1 (en) * | 1999-05-12 | 2000-11-23 | Neurosearch A/S | Ion channel modulating agents |
| CN1377354A (en) * | 1999-09-30 | 2002-10-30 | 纽罗杰有限公司 | Certain alkylenediamine monosubstituted pyrazolo[1,5-a]-1,5-pyrimidines and pyrazolo[1,5-a]-1,3,5-triazines |
| WO2001047514A1 (en) * | 1999-12-23 | 2001-07-05 | Novartis Ag | Use of hypoglycemic agent for treating impaired glucose metabolism |
| PT1145717E (en) * | 2000-04-13 | 2004-08-31 | Pfizer Prod Inc | SYNERGISTIC EFFECT OF GLIBURIDE AND MILRINONE |
| WO2001082916A2 (en) * | 2000-05-03 | 2001-11-08 | Tularik Inc. | Combination therapeutic compositions and methods of use |
| KR100867760B1 (en) * | 2000-05-15 | 2008-11-10 | 소니 가부시끼 가이샤 | Playback device, playback method and recording medium |
| US6627636B2 (en) * | 2000-06-15 | 2003-09-30 | Bristol-Myers Squibb Company | HMG-CoA reductase inhibitors and method |
| US6613308B2 (en) | 2000-09-19 | 2003-09-02 | Advanced Inhalation Research, Inc. | Pulmonary delivery in treating disorders of the central nervous system |
| DE10054481A1 (en) * | 2000-11-03 | 2002-05-08 | Aventis Pharma Gmbh | Acylaminoalkyl-substituted benzenesulfonamide derivatives, their preparation, their use and pharmaceutical compositions containing them |
| US6561075B2 (en) * | 2001-05-09 | 2003-05-13 | Delphi Technologies, Inc. | Power booster with mechanical panic assist function |
| US6492339B1 (en) * | 2001-05-23 | 2002-12-10 | Insmed, Incorporated | Compositions comprising D-chiro inositol and sulfonylureas and methods of treatment thereof |
| EP1529058B1 (en) * | 2002-03-20 | 2013-11-06 | University of Maryland Baltimore | A non-selective cation channel in neural cells and sur1 antagonists for treating brain swelling |
| WO2004093896A1 (en) * | 2003-04-22 | 2004-11-04 | Pharmacia Corporation | Compositions of a cyclooxygenase-2 selective inhibitor and a potassium ion channel modulator for the treatment of central nervous system damage |
| US7326706B2 (en) * | 2003-08-15 | 2008-02-05 | Bristol-Myers Squibb Company | Pyrazine modulators of cannabinoid receptors |
| DE602005023489D1 (en) * | 2004-06-23 | 2010-10-21 | Neurotec Pharma S L | COMPOSITION FOR USE IN THE DIAGNOSIS OF ACUTE INJURIES OF THE CENTRAL NERVOUS SYSTEM |
| CA2580606A1 (en) * | 2004-09-18 | 2006-03-30 | University Of Maryland, Baltimore | Therapeutic agents targeting the ncca-atp channel and methods of use thereof |
| US10583094B2 (en) * | 2004-09-18 | 2020-03-10 | University Of Maryland | Therapeutic methods that target the NCCA-ATP channel |
| EP2167107B1 (en) * | 2007-06-22 | 2016-12-14 | University of Maryland, Baltimore | Inhibitors of ncca-atp channels for therapy |
| US7787809B2 (en) * | 2007-09-10 | 2010-08-31 | Kabushiki Kaisha Toshiba | Image forming apparatus, transfer unit thereof, and method of shifting transfer rollers thereof |
| US7813201B2 (en) * | 2008-07-08 | 2010-10-12 | Atmel Corporation | Differential sense amplifier |
| US9933205B2 (en) | 2011-05-23 | 2018-04-03 | Mitsubishi Electric Corporation | Air-conditioning apparatus |
-
2008
- 2008-02-08 CA CA2618099A patent/CA2618099C/en active Active
- 2008-02-08 US US12/522,802 patent/US20100092469A1/en not_active Abandoned
- 2008-02-08 EP EP08729376.7A patent/EP2114160B1/en active Active
- 2008-02-08 WO PCT/US2008/053405 patent/WO2008098160A1/en not_active Ceased
-
2018
- 2018-05-08 US US15/973,662 patent/US20190111137A1/en not_active Abandoned
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003057843A2 (en) * | 2001-12-31 | 2003-07-17 | Algos Therapeutics, Inc. | Methods and materials for modulating trpc4 |
| US20060276411A1 (en) * | 2002-03-20 | 2006-12-07 | University Of Maryland, Baltimore | Novel non-selective cation channel in neuronal cells and methods for treating brain swelling |
Non-Patent Citations (6)
| Title |
|---|
| FAGAN ET AL: "Targets for vascular protection after acute ischemic stroke", STROKE,, vol. 35, no. 9, 1 September 2004 (2004-09-01), pages 2220 - 2225, XP008116004, DOI: 10.1161/01.STR.0000138023.60272.9E * |
| GURSOY-OZDEMIR ET AL: "Role of Endothelial Nitric Oxide Generation and Peroxynitrite Formation in Reperfusion Injury After Focal Cerebral Ischemia", STROKE,, vol. 31, no. 8, 1 August 2000 (2000-08-01), pages 1974 - 1980, XP008116161 * |
| MANLEY G T ET AL: "AUQPORIN-4 DELETION IN MICE REDUCES BRAIN EDEMA AFTER ACUTE WATER INTOXICATION AND ISCHEMIC STROKE", NATURE MEDICINE, NATURE PUBLISHING GROUP, NEW YORK, NY, US, vol. 6, no. 2, 1 February 2000 (2000-02-01), pages 159 - 163, XP000938619, ISSN: 1078-8956, DOI: 10.1038/72256 * |
| ROSENBERG G A ET AL: "TIMP-2 reduces proteolytic opening of blood-brain barrier by type IV collagenase", BRAIN RESEARCH, ELSEVIER, AMSTERDAM, NL, vol. 576, no. 2, 3 April 1992 (1992-04-03), pages 203 - 207, XP024273625, ISSN: 0006-8993, [retrieved on 19920403], DOI: 10.1016/0006-8993(92)90681-X * |
| See also references of WO2008098160A1 * |
| SIMARD J M ET AL: "Newly expressed SUR1-regulated NCCa-ATP channel mediates cerebral edema after ischemic stroke", NATURE MEDICINE, NATURE PUBLISHING GROUP, NEW YORK, NY, US, vol. 12, no. 4, 1 April 2006 (2006-04-01), pages 433 - 440, XP008117381, ISSN: 1078-8956, [retrieved on 20060319], DOI: 10.1038/NM1390 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2008098160A1 (en) | 2008-08-14 |
| CA2618099A1 (en) | 2008-08-09 |
| EP2114160A1 (en) | 2009-11-11 |
| US20190111137A1 (en) | 2019-04-18 |
| US20100092469A1 (en) | 2010-04-15 |
| EP2114160B1 (en) | 2016-11-16 |
| CA2618099C (en) | 2016-09-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2114160A4 (en) | ANTAGONISTS OF A NON-SELECTIVE CATIONIC CHANNEL IN NEURAL CELLS | |
| BRPI0923351A2 (en) | "multipart dental implant." | |
| TWI561183B (en) | Oral care implement | |
| EP2362759A4 (en) | DENTAL IMPLANT PILLAR | |
| TWI371261B (en) | Bio-activated oral care instrument | |
| EP2111252A4 (en) | Electrochemical management of pain | |
| EP2316414A4 (en) | AFTER SHAMPOO COMPOSITION | |
| BRPI0810555A2 (en) | DENTAL IMPLANT | |
| EP2003722A4 (en) | STACK OF CELLS | |
| EP2427928A4 (en) | ELECTRODE COMPRISING NANOSTRUCTURES FOR RECHARGEABLE CELLS | |
| PL2349491T3 (en) | Sensitivity oral care compositions | |
| BRPI0817965A2 (en) | ORAL CARE IMPLEMENT | |
| BRPI0822833A2 (en) | Oral Care Implement | |
| EP2274413A4 (en) | CONTAINING CELLS | |
| EP2212094A4 (en) | EXTRUSION-BLOW MACHINE AND RELATED MECHANISMS | |
| DK2194959T3 (en) | Foam-proof oral care preparation | |
| EP1989232A4 (en) | CYTOTOXICITY MEDIATION OF CELLS HIGHLIGHTING THE SURFACE EXPRESSION OF CD59 | |
| EP1993477A4 (en) | TRANSPLANTATION OF NEURAL CELLS | |
| EP2215063A4 (en) | EASY N-ALKYLATION OF ACRIDINE COMPOUNDS IN IONIC LIQUIDS | |
| EP2323840A4 (en) | IMPROVEMENTS IN CORRUGATED ROLLS | |
| IL193116A0 (en) | Antagonists of il-18r in diseases | |
| ES1063617Y (en) | TOOTHBRUSH | |
| PL2056787T5 (en) | Denture care composition | |
| EP2226632A4 (en) | METHOD FOR SCREENING AGENT PROTECTING CELLS | |
| BRPI0809817A2 (en) | "TOOTHBRUSH" |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20090825 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR |
|
| DAX | Request for extension of the european patent (deleted) | ||
| RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: UNIVERSITY OF MARYLAND, BALTIMORE Owner name: THE UNITED STATES OF AMERICA, AS REPRESENTED BY TH |
|
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20131111 |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: A01N 45/00 20060101AFI20131105BHEP Ipc: A61K 31/56 20060101ALI20131105BHEP Ipc: A61K 45/06 20060101ALI20131105BHEP |
|
| 17Q | First examination report despatched |
Effective date: 20150225 |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R079 Ref document number: 602008047388 Country of ref document: DE Free format text: PREVIOUS MAIN CLASS: A01N0045000000 Ipc: A61K0031560000 |
|
| GRAJ | Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted |
Free format text: ORIGINAL CODE: EPIDOSDIGR1 |
|
| GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
| GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 25/00 20060101ALI20160503BHEP Ipc: A01N 45/00 20060101ALI20160503BHEP Ipc: A61K 31/56 20060101AFI20160503BHEP Ipc: A61K 45/06 20060101ALI20160503BHEP |
|
| INTG | Intention to grant announced |
Effective date: 20160607 |
|
| GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
| GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
| AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR |
|
| REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
| REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
| REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 845251 Country of ref document: AT Kind code of ref document: T Effective date: 20161215 |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602008047388 Country of ref document: DE |
|
| REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 10 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161116 |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: VENI GMBH, CH |
|
| REG | Reference to a national code |
Ref country code: NL Ref legal event code: MP Effective date: 20161116 |
|
| REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG4D |
|
| REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 845251 Country of ref document: AT Kind code of ref document: T Effective date: 20161116 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161116 Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161116 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170217 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170216 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161116 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170228 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161116 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161116 Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161116 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170316 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161116 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161116 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161116 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161116 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161116 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161116 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161116 |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602008047388 Country of ref document: DE |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161116 Ref country code: BE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161116 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170216 |
|
| PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161116 |
|
| 26N | No opposition filed |
Effective date: 20170817 |
|
| REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161116 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170208 |
|
| REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 11 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170208 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170208 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20080208 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20161116 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161116 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170316 |
|
| P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230522 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20250227 Year of fee payment: 18 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 20250304 Year of fee payment: 18 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20250225 Year of fee payment: 18 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20250227 Year of fee payment: 18 |